Fmr LLC Adagio Therapeutics, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 8,367,757 shares of ADGI stock, worth $27.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,367,757

Previous 8,406,664 0.46%

Holding current value

$27.7 Million

Previous $27.8 Million 0.46%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	N/A	-38,907 Reduced 0.46%	8,367,757 $27.7 Million
Q1 2024 May 13, 2024	SELL	N/A	-5,305 Reduced 0.06%	8,406,664 $27.8 Million
Q4 2023 Feb 13, 2024	BUY	N/A	351,030 Added 4.35%	8,411,969 $27.8 Million
Q3 2023 Nov 13, 2023	SELL	N/A	-1,878,412 Reduced 18.9%	8,060,939 $26.7 Million
Q2 2023 Aug 11, 2023	SELL	N/A	-4,009,584 Reduced 28.74%	9,939,351 $32.9 Million
Q1 2023 May 11, 2023	SELL	N/A	-162,047 Reduced 1.15%	13,948,935 $46.2 Million
Q4 2022 Feb 13, 2023	SELL	$3.08 - $4.05 $3.02 Million - $3.97 Million	-981,424 Reduced 6.5%	14,110,982 $46.7 Million
Q3 2022 Nov 10, 2022	SELL	$2.97 - $4.83 $418,784 - $681,054	-141,005 Reduced 0.93%	15,092,406 $47.2 Million
Q2 2022 Aug 12, 2022	BUY	$2.54 - $4.52 $83 - $149	33 Added 0.0%	15,233,411 $50 Million
Q1 2022 May 13, 2022	SELL	$3.81 - $10.77 $1.37 Million - $3.87 Million	-359,204 Reduced 2.3%	15,233,378 $69.5 Million
Q4 2021 Feb 14, 2022	SELL	$6.35 - $47.04 $6.95 Million - $51.5 Million	-1,095,167 Reduced 6.56%	15,592,582 $110 Million
Q3 2021 Nov 15, 2021	BUY	$20.88 - $56.08 $348 Million - $936 Million	16,687,749 New	16,687,749 $705 Million

Others Institutions Holding ADGI

# of Institutions

Shares Held

67.3M

Call Options Held

720K

Put Options Held

600

View Full List

About Adagio Therapeutics, Inc.

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

More about ADGI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account